These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 15501458

  • 1. WP744 is a novel anthracycline with enhanced activity against neuroblastoma.
    Inge TH, Harris NL, Wu J, Azizkhan RG, Priebe W.
    J Surg Res; 2004 Oct; 121(2):187-96. PubMed ID: 15501458
    [Abstract] [Full Text] [Related]

  • 2. Nuclear factor-kappa B and apoptosis inducing factor activation by doxorubicin analog WP744 in SH-SY5Y neuroblastoma cells.
    Wu J, Harris NL, Inge TH.
    J Surg Res; 2004 Dec; 122(2):231-9. PubMed ID: 15555623
    [Abstract] [Full Text] [Related]

  • 3. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.
    Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W.
    Anticancer Res; 2001 Dec; 21(6A):3777-84. PubMed ID: 11911247
    [Abstract] [Full Text] [Related]

  • 4. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T, Liu X, Thompson PM, Tanaka S, Suita S, Zhao H, Maris JM, Prendergast GC, Hogarty MD.
    Clin Cancer Res; 2003 Aug 15; 9(9):3345-55. PubMed ID: 12960121
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway.
    Yamaguchi Y, Takenobu H, Ohira M, Nakazawa A, Yoshida S, Akita N, Shimozato O, Iwama A, Nakagawara A, Kamijo T.
    Eur J Cancer; 2014 May 15; 50(8):1555-65. PubMed ID: 24559687
    [Abstract] [Full Text] [Related]

  • 8. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.
    Paffhausen T, Schwab M, Westermann F.
    Cancer Lett; 2007 May 18; 250(1):17-24. PubMed ID: 17141950
    [Abstract] [Full Text] [Related]

  • 9. Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death.
    Sagulenko V, Muth D, Sagulenko E, Paffhausen T, Schwab M, Westermann F.
    Carcinogenesis; 2008 Oct 18; 29(10):1869-77. PubMed ID: 18566016
    [Abstract] [Full Text] [Related]

  • 10. Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells.
    Hopkins-Donaldson S, Yan P, Bourloud KB, Muhlethaler A, Bodmer JL, Gross N.
    Oncogene; 2002 Sep 05; 21(39):6132-7. PubMed ID: 12203125
    [Abstract] [Full Text] [Related]

  • 11. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
    Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH.
    Biochem Biophys Res Commun; 2006 Dec 08; 351(1):192-7. PubMed ID: 17055458
    [Abstract] [Full Text] [Related]

  • 12. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
    Wallick CJ, Gamper I, Thorne M, Feith DJ, Takasaki KY, Wilson SM, Seki JA, Pegg AE, Byus CV, Bachmann AS.
    Oncogene; 2005 Aug 25; 24(36):5606-18. PubMed ID: 16007177
    [Abstract] [Full Text] [Related]

  • 13. MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma.
    Manohar CF, Bray JA, Salwen HR, Madafiglio J, Cheng A, Flemming C, Marshall GM, Norris MD, Haber M, Cohn SL.
    Oncogene; 2004 Jan 22; 23(3):753-62. PubMed ID: 14737110
    [Abstract] [Full Text] [Related]

  • 14. 2-Deoxyglucose treatment complements the cisplatin- or BH3-only mimetic-induced suppression of neuroblastoma cell growth.
    Chuang JH, Chou MH, Tai MH, Lin TK, Liou CW, Chen T, Hsu WM, Wang PW.
    Int J Biochem Cell Biol; 2013 May 22; 45(5):944-51. PubMed ID: 23395630
    [Abstract] [Full Text] [Related]

  • 15. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma.
    Liontas A, Yeger H.
    Anticancer Res; 2004 May 22; 24(2B):987-98. PubMed ID: 15161054
    [Abstract] [Full Text] [Related]

  • 16. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model.
    Kotchetkov R, Cinatl J, Blaheta R, Vogel JU, Karaskova J, Squire J, Hernáiz Driever P, Klingebiel T, Cinatl J.
    Int J Cancer; 2003 Mar 10; 104(1):36-43. PubMed ID: 12532417
    [Abstract] [Full Text] [Related]

  • 17. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
    Smith AG, Popov N, Imreh M, Axelson H, Henriksson M.
    J Cell Biochem; 2004 Aug 15; 92(6):1282-95. PubMed ID: 15258910
    [Abstract] [Full Text] [Related]

  • 18. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
    Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, Vacca A, Ponzoni M.
    Int J Cancer; 2002 Dec 01; 102(4):351-4. PubMed ID: 12402304
    [Abstract] [Full Text] [Related]

  • 19. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL, Onda K, Tanaka S, Toma T, Hirano T, Oka K.
    Cancer Chemother Pharmacol; 2002 May 01; 49(5):391-7. PubMed ID: 11976833
    [Abstract] [Full Text] [Related]

  • 20. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
    Liu X, Mazanek P, Dam V, Wang Q, Zhao H, Guo R, Jagannathan J, Cnaan A, Maris JM, Hogarty MD.
    Oncogene; 2008 Feb 28; 27(10):1478-88. PubMed ID: 17724465
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.